Sector Gamma AS grew its position in shares of Qiagen NV (NYSE:QGEN) by 14.4% during the third quarter, Holdings Channel reports. The firm owned 484,601 shares of the company’s stock after acquiring an additional 61,100 shares during the quarter. Qiagen makes up approximately 2.7% of Sector Gamma AS’s portfolio, making the stock its 13th biggest holding. Sector Gamma AS’s holdings in Qiagen were worth $15,977,000 at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Private Capital Group LLC increased its position in shares of Qiagen by 354.0% during the second quarter. Private Capital Group LLC now owns 681 shares of the company’s stock worth $25,000 after acquiring an additional 531 shares during the period. Quest Capital Management Inc. ADV purchased a new stake in shares of Qiagen during the third quarter worth $37,000. Huntington National Bank increased its position in shares of Qiagen by 33.3% during the third quarter. Huntington National Bank now owns 1,568 shares of the company’s stock worth $52,000 after acquiring an additional 392 shares during the period. Tower Research Capital LLC TRC increased its position in shares of Qiagen by 1,244.7% during the second quarter. Tower Research Capital LLC TRC now owns 1,385 shares of the company’s stock worth $56,000 after acquiring an additional 1,282 shares during the period. Finally, Bessemer Group Inc. increased its position in shares of Qiagen by 5,918.5% during the second quarter. Bessemer Group Inc. now owns 1,625 shares of the company’s stock worth $66,000 after acquiring an additional 1,598 shares during the period. Institutional investors own 62.19% of the company’s stock.
Several equities analysts recently commented on QGEN shares. UBS Group reissued a “neutral” rating on shares of Qiagen in a report on Wednesday, October 9th. DZ Bank reissued a “neutral” rating on shares of Qiagen in a report on Wednesday, July 24th. TheStreet lowered Qiagen from a “b-” rating to a “c+” rating in a report on Friday, October 18th. Zacks Investment Research raised Qiagen from a “sell” rating to a “hold” rating and set a $32.00 target price on the stock in a report on Monday, November 4th. Finally, Berenberg Bank reissued a “buy” rating on shares of Qiagen in a report on Tuesday, October 1st. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have issued a buy rating to the stock. Qiagen presently has a consensus rating of “Hold” and an average price target of $33.57.
NYSE:QGEN traded up $0.30 during trading hours on Friday, hitting $31.61. The company’s stock had a trading volume of 1,132,065 shares, compared to its average volume of 1,277,807. The stock has a market capitalization of $6.83 billion, a P/E ratio of 23.59, a price-to-earnings-growth ratio of 2.26 and a beta of 0.83. The stock has a fifty day moving average of $30.20 and a 200-day moving average of $35.78. The company has a current ratio of 2.45, a quick ratio of 2.18 and a debt-to-equity ratio of 0.68. Qiagen NV has a 52-week low of $25.04 and a 52-week high of $41.55.
Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $0.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.35 by $0.01. The company had revenue of $382.70 million for the quarter, compared to analyst estimates of $382.98 million. Qiagen had a positive return on equity of 12.24% and a negative net margin of 1.68%. The business’s quarterly revenue was up 1.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.35 earnings per share. On average, sell-side analysts forecast that Qiagen NV will post 1.4 earnings per share for the current year.
Qiagen Company Profile
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
Further Reading: What is systematic risk?
Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen NV (NYSE:QGEN).
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.